Biotech Values

[DewDiligence]

MNTA/Lovenox update from AMPH’s 3Q15 CC: AMPH is now boasting that it has “strong defenses” in the Lovenox patent trial that has been remanded to the US District Court (#msg-118404904); however, AMPH’s executives are no longer talking about collecting on NVS/MNTA’s $100M District Court bond that has been held by the Court since Oct 2011, pending a final outcome in the patent case.

This is a big change from AMPH’s previous CCs.